# Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

> **NCT04736173** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Arcus Biosciences, Inc.** · enrollment: 169 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** Domvanalimab
- **DRUG:** Zimberelimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04736173
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-08
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736173, "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04736173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*